Introduction: Beyond Purchase Price – Redefining Value in Pharma Procurement In the intricate and high-stakes world of pharmaceutical procurement, the […]

Litigation Summary and Analysis for Bristol-Myers Squibb Company v. Azurity Pharmaceuticals, Inc. | 1:25-cv-01558 Executive Summary This litigation revolves around

Part I: The Hatch-Waxman Gauntlet: Foundational Principles and Economic Stakes 1.1 The Grand Compromise: Deconstructing the Hatch-Waxman Act The modern

I. Introduction: A Precarious Symbiosis The United States healthcare landscape is shaped by a complex web of federal statutes, each

Introduction: The End of an Era and the Dawn of a New Playbook The generic pharmaceutical industry operates at the

For decades, the pharmaceutical industry’s center of gravity was firmly anchored in the mature, high-margin markets of North America, Western

Executive Summary The expiration of a drug’s patent is one of the most predictable and disruptive events in the pharmaceutical

Introduction: Beyond the Blueprint In the high-stakes, multi-billion-dollar world of pharmaceuticals, the Abbreviated New Drug Application (ANDA) is far more

I. The Modern Pharmaceutical Crucible: Navigating the Economics of Erosion and Uncertainty The pharmaceutical industry operates within a crucible of